Wockhardt Limited
WOCKPHARMA
Rang in Aktien
#4551
Wockhardt Limited, together with its subsidiaries, operates as a pharmaceutical... Wockhardt Limited, together with its subsidiaries, operates as a pharmaceutical and biotech company, in India, the United States, the United Kingdom, Switzerland, Ireland, Russia, Europe, and internationally. It manufactures and trades pharmaceuticals, medicinal chemical, and botanical products, as well as chemicals and chemical products. The company also develops its flagship antibiotic, ZAYNICH zidebactam/cefepime, a novel beta lactam enhancer mechanism for the treatment of sepsis and hospital/ventilator associated pneumonia; FOVISCU, an antibiotic for gram-negative infections; MIQNAF nafithromycin, which targets azithromycin-resistant community respiratory pathogens; and ODRATE, a once-daily combination of ertapenem and zidebactam for resistant gram-negative infections through outpatient parenteral antimicrobial therapy. In addition, it develops and commercializes insulin analogs, glucagon-like peptide-1 agonists, and novel combination drug products; Biovac-B, a recombinant hepatitis-B vaccine; Wepox, a recombinant human erythropoietin; Wosulin, a recombinant human insulin; and Glaritus, a recombinant insulin glargine. Further, the company offers delivery devices for insulin, including Dispopen disposable pen and Mypen reusable pen. Wockhardt Limited was founded in 1967 and is headquartered in Mumbai, India.
Aktienkurs
$20.75
Marktkapitalisierung
$3.37B
Veränderung (1 Tag)
-1.38%
Veränderung (1 Jahr)
33.03%
Land
IN
Handel Wockhardt Limited (WOCKPHARMA)
Kategorie
Healthcare
Umsatz von Wockhardt Limited (WOCKPHARMA)
Umsatz im Jun 2026 TTM: $393.32M
Laut den aktuellen Finanzberichten von Wockhardt Limited beträgt der derzeitige Umsatz des Unternehmens (TTM) $393.32M. Im Jahr 2024 erzielte das Unternehmen einen Umsatz von $339.40M eine Steigerung gegenüber dem Umsatz im Jahr 2023, der $323.31M betrug. Der Umsatz ist der Gesamtbetrag, den ein Unternehmen durch den Verkauf von Waren oder Dienstleistungen erzielt. Im Gegensatz zum Gewinn werden keine Ausgaben abgezogen.
Umsatzverlauf für Wockhardt Limited von 2004 bis 2026
Umsatz am Ende jedes Jahres
| Jahr | Umsatz | ändert |
|---|---|---|
| 2026 (TTM) | $393.32M | 10.84% |
| 2025 | $354.86M | 4.56% |
| 2024 | $339.40M | 4.97% |
| 2023 | $323.31M | -24.02% |
| 2022 | $425.51M | 15.02% |
| 2021 | $369.93M | -2.01% |
| 2020 | $377.51M | -26.48% |
| 2019 | $513.51M | -14.80% |
| 2018 | $602.74M | -1.45% |
| 2017 | $611.63M | -9.01% |
| 2016 | $672.19M | -6.41% |
| 2015 | $718.21M | -10.88% |
| 2014 | $805.87M | -22.17% |
| 2013 | $1.04B | 13.80% |
| 2012 | $909.89M | 8.10% |
| 2011 | $841.74M | -16.02% |
| 2010 | $1.00B | 35.33% |
| 2008 | $740.59M | 9.85% |
| 2007 | $674.18M | 72.85% |
| 2006 | $390.03M | 24.39% |
| 2005 | $313.56M | 9.96% |
| 2004 | $285.15M | 0.00% |
Umsatz vergleichbarer Unternehmen oder Wettbewerber
| Unternehmen | Umsatz | Umsatzunterschied | Land |
|---|---|---|---|
| $2.54B | 544.77% |
US
|
|
| - | - |
SE
|
|
| - | - |
FR
|
|
| - | - |
IT
|
|
| $830.81M | 111.23% |
US
|
